Literature DB >> 2547172

Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease.

F Hefti1, D C Mash.   

Abstract

NGF receptors were visualized in human brain sections with an immunohistochemical procedure using a monoclonal antibody. This method results in the selective visualization of a population of neurons in the medial septal nucleus, the nucleus of the diagonal band of Broca, and the nucleus basalis of Meynert. Several lines of evidence indicate that this neuronal population is identical to the cholinergic neurons of the basal forebrain. NGF receptor immunohistochemistry therefore represents a sensitive and reliable procedure to selectively visualize forebrain cholinergic neurons for post-mortem analysis. NGF receptors were found to be expressed during the entire life span. However, the intracellular staining intensity was reduced in normal aging, suggesting the tentative conclusion that NGF receptor synthesis may decline in the aged brain. In Alzheimer's disease, the number of NGF receptor-positive cells was decreased. The morphological characteristics of surviving neurons were similar to immuno-positive neurons visualized in normal aged brains.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547172     DOI: 10.1016/s0197-4580(89)80014-4

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  19 in total

Review 1.  Nerve growth factor and neuronal cell death.

Authors:  J R Perez-Polo; P J Foreman; G R Jackson; D Shan; G Taglialatela; L W Thorpe; K Werrbach-Perez
Journal:  Mol Neurobiol       Date:  1990 Spring-Summer       Impact factor: 5.590

2.  Recombinant human nerve growth factor is biologically active and labels novel high-affinity binding sites in rat brain.

Authors:  C A Altar; L E Burton; G L Bennett; M Dugich-Djordjevic
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

3.  Neurotrophic Peptides: Potential Drugs for Treatment of Amyotrophic Lateral Sclerosis and Alzheimer's disease.

Authors:  Jessica Ciesler; Youssef Sari
Journal:  Open J Neurosci       Date:  2013-04-08

4.  Measurement of human nerve growth factor binding sites in brain and in peripheral tissues by a specific immunoprecipitation assay.

Authors:  P Ehrhard; F Gudat; U Otten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

5.  Overexpression of hsa-miR-939 follows by NGFR down-regulation and apoptosis reduction.

Authors:  Fahimeh Hosseini Aghdaei; Bahram M Soltani; Sadat Dokanehiifard; Seyed Javad Mowla; Masoud Soleimani
Journal:  J Biosci       Date:  2017-03       Impact factor: 1.826

6.  Cholinergic profiles in the Goettingen miniature pig (Sus scrofa domesticus) brain.

Authors:  Laura J Mahady; Sylvia E Perez; Dwaine F Emerich; Lars U Wahlberg; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2016-08-30       Impact factor: 3.215

7.  TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin.

Authors:  T Sobreviela; D O Clary; L F Reichardt; M M Brandabur; J H Kordower; E J Mufson
Journal:  J Comp Neurol       Date:  1994-12-22       Impact factor: 3.215

8.  Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats.

Authors:  A Nitta; Y Murakami; Y Furukawa; W Kawatsura; K Hayashi; K Yamada; T Hasegawa; T Nabeshima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-04       Impact factor: 3.000

9.  Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer disease.

Authors:  E J Mufson; J H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

Review 10.  Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.

Authors:  Tomohiro Chiba; Ikuo Nishimoto; Sadakazu Aiso; Masaaki Matsuoka
Journal:  Mol Neurobiol       Date:  2007-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.